Astellas Signs a License Agreement with Welldoc to Develop and Commercialize Digital Therapies

 Astellas Signs a License Agreement with Welldoc to Develop and Commercialize Digital Therapies

Astellas Signs a License Agreement with Welldoc to Develop and Commercialize Digital Therapies

Shots:

  • Welldoc to receive $15M upfront, development & commercialization milestones and royalties on sales. Astellas and Welldoc will jointly develop and commercialize BlueStar for patients with diabetes in Asian countries including Japan
  • The companies will co-develop & co-commercialize digital therapies globally for multiple therapeutic areas. The collaboration allows Welldoc to widen its platform in other therapeutic areas and expand its presence in global markets including the US while allowing Astellas to develop its Rx+ programs
  • Welldoc’s BlueStar is a digital health solution that assists patients aged ≥18yrs. in managing their diabetes (T1D, T2D) and utilizes machine learning to aid self-management of diabetes and has received FDA’s approval in 2010 following 6 additional 510(k) clearances from the US FDA

Source1, Source2 to­ read full press release/ article | Ref: Astellas, Welldoc | Image:  Welldoc

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post